| Apolipoprotein measurements: is more widespread use clinically indicated? | |
MedLine Citation:
|
PMID: 19743499 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Apolipoprotein (apo) B may be a more sensitive measure of atherogenicity than low-density lipoprotein cholesterol (LDL-C) and a better index for assessing cardiovascular risk. The refined risk assessment provided by apo B may be important in patients at high cardiometabolic risk such as those with diabetes mellitus or metabolic syndrome, as these conditions are often associated with normal LDL-C values but increased numbers of small, dense low-density lipoprotein (LDL) particles (indicating increased levels of apo B). Although apo B is not currently a treatment target in the United States cholesterol-lowering guidelines, a consensus conference endorsed by the American Diabetes Association and the American College of Cardiology recently recommended that apo B be added as a therapeutic target in patients at high cardiometabolic risk and in patients with clinical cardiovascular disease or diabetes. Suggested target goals are < 90 for high risk and < 80 mg/dL for highest risk patients. Current clinical data indicate that intensive statin therapy can lower apo B to meet this aggressive goal. While the proatherogenic/antiatherogenic ratio of apo B/apo A-I is a better risk discriminator than the single proatherogenic measurement (apo B), clinical trial data are lacking regarding the impact of increasing apo A-I and high-density lipoprotein on outcomes. |
Authors:
|
Michael H Davidson |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Clinical cardiology Volume: 32 ISSN: 1932-8737 ISO Abbreviation: Clin Cardiol Publication Date: 2009 Sep |
Date Detail:
|
Created Date: 2009-09-16 Completed Date: 2009-11-23 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7903272 Medline TA: Clin Cardiol Country: United States |
Other Details:
|
Languages: eng Pagination: 482-6 Citation Subset: IM |
Copyright Information:
|
Copyright 2009 Wiley Periodicals, Inc. |
Affiliation:
|
Preventive Cardiology Center, University of Chicago Pritzker School of Medicine, Chicago, Illinois, USA. michaeldavidson@radiantresearch.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Apolipoprotein A-I
/
blood* Apolipoproteins B / blood* Atherosclerosis / blood*, complications, drug therapy Biological Markers / blood Cardiovascular Diseases / blood, etiology*, prevention & control Cholesterol, HDL / blood Cholesterol, LDL / blood Diabetes Mellitus / blood Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use Metabolic Syndrome X / blood, complications Practice Guidelines as Topic Predictive Value of Tests Risk Assessment Risk Factors |
| Chemical | |
Reg. No./Substance:
|
0/APOA1 protein, human; 0/Apolipoprotein A-I; 0/Apolipoproteins B; 0/Biological Markers; 0/Cholesterol, HDL; 0/Cholesterol, LDL; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: No Article Title
Next Document: Combined use of pharmacokinetic modeling and a steady-state delivery approach allows early assessmen...